UA was defined according to the Braunwald Classification with creatine kinase (CK) and CK-MB isozyme values not greater than twice the respective upper limits of normal; a diagnosis of AMI was made if the CK and CK-MB values exceeded twice the upper limits of normal and the time from onset to admission was within 24 h.
Study 1: Questionnaire Survey
A questionnaire composed of the 8 questions listed below was sent to the 770 sites certified for cardiovascular care by the Japanese Circulation Society. To increase the response rate and to avoid null answers, multiple choice responses to the questions were set, as shown in parentheses below.
UA (1) Approximate number of hospitalized UA patients during the year from January to December 2000 (≤25; 26-50; 51-100; 101-200; >200).
(2) Treatment with heparin immediately after hospital arrival, excluding bolus administration for coronary angiography and/or revascularization (for all patients apart from those with contraindications; only for refractory patients not responding to appropriate antianginal treatment or for severe cases; not used in principle).
(3) Timing of coronary angiography (immediately after arrival at hospital; after stabilization by drug treatment; not performed if stabilized by drug treatment; no definite policy).
(4) Use of heparin after percutaneous coronary intervention (PCI) (not used in principle; for some patients; for all patients in principle).
AMI (1) Approximate number of hospitalized AMI patients during the year from January to December 2000 (3) Treatment principles (first-line treatment) for STelevation and non-ST-elevation AMI (invasive therapy is first choice for both types; invasive therapy is first choice for ST-elevation and for non-ST-elevation first choice is drug treatment followed by invasive therapy; other methods).
Study 2: Case Report Investigation
Twenty sites (Table 1) were randomly selected from among those participating in the questionnaire survey (study 1) and were requested to submit case reports for 50 consecutive patients treated for UA and 50 treated for AMI after January 2000. A case report was to include the following information.
Demographic Data and Clinical Profile Sex, age, concomitant disease, previous disease, time from onset to admission, Braunwald classification (only for UA patients), and ECG findings. Hypertension, hyperlipidemia, diabetic, kidney disease, and liver disease that were concomitant diseases were diagnosed by individual investigator based on the diagnostic standard of each site.
Treatment Findings of coronary angiography, details Table 2 . of revascularization, use of heparin, use of oral antiplatelet drugs, use of antianginal drugs (only for UA patients).
Outcome All-cause death, AMI, and urgent coronary revascularization during the first 6 months, as well as inhospital major bleeding events.
In this study, information about medical treatment with nicorandil, ACE inhibitors, ARBs and statins, and information of device usage (thrombectomy or distal protection) was not included.
Prior to initiation, the protocol and conduct of the study were approved by the ethical committee or institutional review board of each participating site.
Results

Study 1: Questionnaire Survey
Of the 770 sites, 584 responded to the questionnaire (response rate of 76%).
Number of Patients No more than 25 patients with UA were hospitalized annually at 274 of the 582 sites (48%). The annual number of UA patients was 26-50 at 186 sites (32%), 51-100 at 90 sites (15%), and greater than 100 at 32 sites (5%) (Fig 1) .
The annual number of AMI patients was no greater than 25 at 194 of the 580 sites (33%), 26-50 at 175 sites (30%), 51-100 at 146 sites (25%), and greater than 100 at 65 sites (12%). In general there were fewer UA patients than AMI patients at each site (Fig 2) . To obtain a more accurate estimate of the number of UA patients relative to AMI patients, another questionnaire was sent to the 389 sites that reported treating more than 25 AMI patients per year. Of these, 217 (56.1%) responded to the additional questionnaire. The total annual number of UA and AMI patients at the 217 sites was 9,656 and 15,102, respectively, a ratio of 1:1.56. Among the 15,102 AMI patients, 2,535 (17%) were diagnosed as non-STelevation AMI (Fig 4) .
Treatment Provided (1) Timing of coronary angiography -"after stabilization by drug treatment" was the most frequent response chosen by 341 of the 574 sites (59%). Patients underwent coronary angiography as soon as possible after arrival at 211 sites (37%) (Fig 5) .
(2) Use of heparin -Heparin was administered immediately after arrival at hospital to all patients without contraindications at 411 of the 582 sites (70%). The next most frequent choice was "only refractory patients not responding to appropriate antianginal treatment or for severe cases", the management selected by 133 sites (23%) (Fig 6) .
After PCI, heparin was used in principle at 333 of the 521 sites (64%), but was not usually administered at 112 sites (21%) (Fig 7) .
(3) Treatment of ST-elevation and non-ST-elevation AMI -most of the sites (83%; 477/576) used invasive therapy as first-line treatment of AMI of both types (Fig 8) .
Study 2: Case Report Investigation
The 20 randomly selected sites submitted case reports on 885 UA patients and 937 AMI patients.
Baseline characteristics of the UA patients were similar to those of the AMI patients with respect to sex, age, and concomitant disease. The median time from symptom onset to admission of the UA patients was 15.25 h, substantially longer than for the AMI patients. Among the UA patients, 62% were classified as Braunwald Class III. Among the AMI patients, 17% were diagnosed as non-ST-elevation AMI (Tables 2,3) .
Among the UA patients, 92% underwent coronary angiography and 73% underwent coronary revascularization: percutaneous transluminal coronary angioplasty in 80%, coronary stenting in 63%, and CABG in 16%. The median time from admission to revascularization was 57 h for the UA patients, much longer than the 1.5 h for the AMI patients. A lower percentage of UA patients (68%) than AMI patients (82%) received continuous infusion of heparin (Tables 4,5) .
Cardiac events occurred in 21 UA patients (2.0%) during Table 2 . Table 2 . the first month and in 78 patients (9.0%) during the initial 6 months. During hospitalization, 37 UA patients (4.0%) experienced severe hemorrhagic events. Both cardiac events and severe hemorrhagic events were less frequent in the UA patients than in the AMI patients (Tables 6,7) . Table 8 shows the 6-month incidence of cardiac events stratified by baseline characteristics of the UA patients. The incidence of cardiac events was significantly higher in patients with renal disease than in those without renal disease. Cardiac events were more frequent in women, patients with a history of myocardial infarction (MI), and patients with diabetes. The incidence of cardiac events was significantly higher in patients with ST segment changes on admission than in those without such changes. It was also higher, but not significantly so, in patients with T-wave inversion than in those without T-wave inversion. The incidence of cardiac events tended to increase with the severity of Braunwald classification. Table 9 shows the 6-month incidence of cardiac events in UA patients stratified by treatment. With regard to antianginal therapy, the incidence of cardiac events was significantly lower in those treated with an oral calcium-channel blocker than in those not so treated. The incidence of cardiac events was also significantly lower in those undergoing coronary angiography after arrival at hospital than in those not undergoing it. Neither use of heparin nor revascularization was significantly associated with the incidence of cardiac events. Cardiac events did not occur in any of the patients without significant stenosis on initial coronary angiography. The outcome was worse in patients with significant stenosis persisting after revascularization than in those without.
Events Stratified by Clinical Profile and Treatment
Because oral calcium-channel blockers are suggested to reduce the risk of cardiac events in UA patients, the effects of the most commonly used drugs of this class (eg, diltiazem, amlodipine, and nifedipine) were evaluated. The incidence of cardiac events was lower in patients taking amlodipine than in those not taking it (Table 10) .
The relationship of the timing of treatment with calciumchannel blockers to the risk of cardiac events was evaluated and the incidence of cardiac events was lower in patients who started treatment with a calcium blocker after admission than in those who were continuously treated before the onset of UA, although the difference was not significant (Table 11) .
Tables 12 and 13 summarize the 6-month incidence of cardiac events in AMI patients stratified by clinical profile and by treatment, respectively. Clinical factors that were associated with a significantly higher incidence of cardiac events were female sex, age ≥65 years, a history of angina pectoris, a history of MI, hypertension, renal disease, detection of acute heart failure on admission, and complete left bundle branch block on ECG.
The treatments associated with a significantly lower incidence of cardiac events were heparin, oral antiplatelet drugs (aspirin or ticlopidine), coronary angiography, and reperfusion therapy. Cardiac events even occurred in some AMI patients without significant stenosis on initial coronary angiography.
Discussion
Our questionnaire survey revealed that fewer patients are hospitalized with UA than with AMI in Japan. Among several overseas studies that simultaneously investigated the number of UA and AMI patients, a Spanish study of inpatients reported similar results, with an approximate ratio of 1:2 for UA patients vs AMI patients. 8 Of 2 investigations of patients admitted to the ICU or CCU, 1 showed that the number of AMI patients was more than twice that of UA patients, 9 and the other revealed that UA patients outnumbered AMI patients by a ratio of 1.5 to 1. 10 The ratio of UA vs AMI patients obtained in the present study, which involved inpatients only, might be different if those treated as outpatients had been included. Because the largest percentage of UA patients in the case report investigation had Braunwald class III disease, those with Braunwald class I or II disease may have been treated on an outpatient basis. This finding should be taken into consideration when developing the recommendations for treatment of UA because inpatient care is standard management for suspected UA.
The results of both the questionnaire survey and the case report investigation indicate that non-ST-elevation AMI accounts for 15-20% of all AMI, a finding that is also consistent with overseas data. 11 The present study showed that both ST-elevation and non-ST-elevation AMI are managed in Japan according to the principle of early invasive therapy as first-line treatment. Although the ACC/AHA and Japanese guidelines for the management of ACS recommend different treatment pathways for ST-elevation and non-ST-elevation AMI, it seems acceptable in practice to make no distinction between the 2 types of AMI in Japan. Compared with the USA and Europe, in Japan a larger proportion of institutions are capable of providing coronary intervention relative to the number of patients with ischemic heart disease.
The present study also showed a trend toward early invasive treatment of UA, especially those cases of Braunwald class III disease (median time from admission to conduct the invasive treatment of Braunwald classes I, II and III was 144, 79 and 34 h, respectively). However, UA patients received invasive treatment later than AMI patients and were usually given drug treatment immediately after arrival at hospital. Because the present study investigated the medical management of UA in 2000, these patients may now receive invasive treatment earlier because of subsequent improvements in the devices for coronary intervention and the skills of the interventionists. However, a GUSTO-IV substudy recently demonstrated that patients with non-STelevation ACS showing low levels of biomarkers have a very low 1-year mortality with medical management, and early invasive procedures appear to increase their overall risk of mortality. 12 That study may be a warning against early invasive management in UA patients.
According to the present case report data, approximately 70% of patients received continuous infusion of heparin immediately after admission, which indicates that heparin is regarded as essential if medical treatment is used to stabilize the patient in the early hospital phase.
In UA patients, the incidence of cardiac events was 2% at 1 month and 9% at 6 months, which is lower than in AMI patients for both time intervals. Previous overseas studies of patients with non-ST-elevation ACS have revealed a higher incidence of cardiac events, 13, 14 suggesting that the prognosis of UA may be better in Japanese patients. Although many of the patients were treated with antithrombotic drugs, such as heparin, aspirin, and ticlopidine, only 4% of them experienced major bleeding events during hospitalization and none of them developed intracranial hemorrhage, which suggests that the use of antithrombotic drugs was appropriate, with adequate precautions taken to prevent bleeding complications.
The results of the stratified analyses of the 6-month outcomes in UA patients should be interpreted carefully because of the nonrandomized, retrospective design of this study. For example, our analysis in UA patients failed to detect any significant difference in the incidence of cardiac events between patients undergoing or not undergoing PCI and between those with or without heparin infusion. Patients who undergo PCI or who receive heparin usually have more severe disease than those not receiving these treatments and this difference in severity may have masked the beneficial effect of such treatments on the outcome.
On the other hand, the incidence of cardiac events in patients using any calcium-channel blocker was significantly lower than those in patients who had not received calciumchannel blocker and these 2 subgroups had similar clinical profiles (data not shown). This suggests that calciumchannel blocker therapy may be an independent determinant of the prognosis of UA. Because it has long been known that coronary vasospasm plays a greater role in the etiology of ischemic heart disease in Japanese than in Caucasians, the reduction of cardiac events observed in patients treated with calcium-channel blockers may reflect the ability of drugs in this class to suppress coronary vasospasm. 15 However, a randomized clinical trial should be carried out to confirm the efficacy of calcium blockers in the treatment of ACS in Japanese patients.
There was no significant difference in the stratified analysis of cardiac events by infarct location (Table 12) . Concerning the relationship between infarct location and long-term prognosis, there is not consensus. Kandzari et al reported that the long-term prognosis of anterior infarction was worse than for other infarction sites, 16 Abbreviations as in Tables 2, 8, 12. reported that there was no significant difference in longterm prognosis by infarct location. 17 As shown in Table 13 , there was no apparent difference in the incidence of cardiac events between patients obtaining Thrombolysis In Myocardial Infarction (TIMI) 3 flow after reperfusion therapy and patients who did not. It is well known that TIMI 0 to TIMI 2 flow is an independent predictor of prognosis 18, 19 and the reason why our result was different from previous reports is unclear.
With the cooperation of many cardiovascular specialists, the present nationwide investigation has provided the first insight into the actual management of ACS (including UA) in Japan. It is of great importance to develop appropriate treatments for Japanese patients based on the specific characteristics of this population.
Therefore, more studies in patients with ACS and AMI should be performed in the future. In particular, it would be valuable to collect information about medical treatment with nicorandil, ACE inhibitors, ARBs and statins, and invasive treatments (drug-eluting stents, distal protection devices, thrombectomy, etc).
